Clinical Trial

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-04-08; most recent amendment 2026-01-29.
Status change: Not Yet Recruiting → Recruiting 2025-05-07
Trial Details
NCT Number NCT06926920
Lead Sponsor Gilead Sciences
Conditions Triple Negative Breast Cancer
Enrollment 100 participants
Start Date 2025-04-30
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-30